Division of Hemato-Oncology, Department of Internal Medicine, School of Medicine, Wonkwang University, 321 Sanbonro, Gunpo, 15865 Gyeonggi-do, Republic of Korea.
Biomed Res Int. 2021 May 5;2021:2068023. doi: 10.1155/2021/2068023. eCollection 2021.
Management of endometrial cancer, an adenocarcinoma of the endometrium which occupies most uterine corpus neoplasms, including uterine sarcomas, has been more relevant due to its increasing incidence. Extensive research on tumorigenesis molecular mechanisms and molecular characterization across cancers has brought paradigm shifts in the treatment of various malignant tumors. Endometrial cancer treatment has been traditionally guided according to the disease extent or histology types, while recent studies on molecular features have led to the introduction of targeted agents into clinical use, along with conventional chemotherapeutic agents in patients with recurrent or metastatic disease. Considering the proven efficacy and relatively tolerable toxicities of targeted therapies across malignant tumors, improvement of treatment outcomes is also expected in endometrial cancer by adopting an individualized therapy depending on the specific molecular features. Efficacy assessment of new biological agents is still ongoing based on previous preclinical data on endometrial cancer molecular features. Here, endometrial cancer molecular characterization will be reviewed, and then, we will introduce preclinical data, directing the adoption of new biological agents.
子宫内膜癌的管理，一种子宫内膜的腺癌，占据了大多数子宫体肿瘤，包括子宫肉瘤，由于其发病率的增加而变得更加相关。对肿瘤发生的分子机制和癌症分子特征的广泛研究，给各种恶性肿瘤的治疗带来了范式转变。子宫内膜癌的治疗传统上是根据疾病的程度或组织学类型来指导的，而最近对分子特征的研究导致了靶向药物的引入，以及在复发或转移性疾病患者中使用传统化疗药物。考虑到靶向治疗在各种恶性肿瘤中的疗效已被证实，且毒性相对可耐受，通过根据特定的分子特征采用个体化治疗，预计子宫内膜癌的治疗结果也将得到改善。新的生物制剂的疗效评估仍在基于子宫内膜癌分子特征的先前临床前数据进行中。在这里，我们将回顾子宫内膜癌的分子特征，并介绍指导新生物制剂采用的临床前数据。
